Ascendis Pharma A/S vs Blackstone Inc — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Blackstone Inc trades at $147.54 (market cap $117.44B). The key difference: Blackstone Inc is far larger — about 7× Ascendis Pharma A/S's market cap, and Blackstone Inc pays a 3.55% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BX | |
|---|---|---|
Market Cap | $16.67B | $117.44B |
Sector | Health | Financials |
52-Week High | $277.18 | $188.68 |
52-Week Low | $189.74 | $102.12 |
Enterprise Value | $17.04B | — |
Dividend Yield | — | 3.55% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →